The abetalipoproteinemia management market is projected to grow from USD 0.2 billion in 2025 to USD 0.4 billion by 2035, at a CAGR of 8.2%. Molecular Genetic Testing Treatment will dominate with a 38.6% market share, while hospitals & clinics will lead the end user segment with a 54.2% share.